New Weight-Loss drug CPX101 enters human testing
NCT ID NCT06545162
First seen Apr 17, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This early-phase study tested a new drug called CPX101 in 72 healthy volunteers and overweight or obese patients. The main goal was to check if the drug is safe and tolerable, and to see how the body processes it. Researchers also looked at whether multiple doses could help with weight loss. The study was completed, but results are not yet public.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Friendship Hospital
Beijing, Beijing Municipality, 100000, China
-
Beijing Luhe hospital
Beijing, Beijing Municipality, 100000, China
-
Beijing hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.